Tetrous, Inc. is a regenerative medicine company which is guided by a team of influential surgeons, and regenerative medicine scientists, and led by experienced Medical Device executives. Tetrous has developed the next generation of advanced technologies for tissue repair in sports medicine and wound care. Tetrous has three synergistic technology platforms. The first of these is a proprietary and patented process for making demineralized bone fibers (TheraFuze DBF®). The second platform is a patented process for creating procedure specific implants for rotator cuff repair and other sports medicine procedures as well as wound care. The third technology platform is a range of proprietary and patented oxygenation technologies. Oxygenation leads to improved tissue regeneration. Tetrous has licensed methodologies and gained patent protection for applying the oxygenation technology to bone and wound products. Founded in 2019, the firm is headquartered in Los Angeles and maintains offices, laboratories and production facilities in the Boston area.

TheraCell DBF®, DBF and TheraCell are trademarks of TheraCell, Inc.